Review



antibody against ctag2  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Bioss antibody against ctag2
    Hub gene score according to the four topological analysis methods.
    Antibody Against Ctag2, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody against ctag2/product/Bioss
    Average 90 stars, based on 2 article reviews
    antibody against ctag2 - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Identification of cancer/testis antigen 2 gene as a potential hepatocellular carcinoma therapeutic target by hub gene screening with topological analysis"

    Article Title: Identification of cancer/testis antigen 2 gene as a potential hepatocellular carcinoma therapeutic target by hub gene screening with topological analysis

    Journal: Oncology Letters

    doi: 10.3892/ol.2019.10811

    Hub gene score according to the four topological analysis methods.
    Figure Legend Snippet: Hub gene score according to the four topological analysis methods.

    Techniques Used:

    Kaplan-Meier curves indicating the correlation of the overall survival of hepatocellular carcinoma patients with different hub genes, including: (A) CTAG2 (P=0.034); (B) NTS (P=0.736); (C) GNG4 (P=0.185); (D) GAST (P=0.053); (E) PRSS1 (P=0.436); and (F) PRSS3 (P=0.317). The patients were divided into two groups according to the expression of hub genes. The blue curve represents the low-expression group, while the green curve represents the high-expression group. CTAG2, cancer/testis antigen 2.
    Figure Legend Snippet: Kaplan-Meier curves indicating the correlation of the overall survival of hepatocellular carcinoma patients with different hub genes, including: (A) CTAG2 (P=0.034); (B) NTS (P=0.736); (C) GNG4 (P=0.185); (D) GAST (P=0.053); (E) PRSS1 (P=0.436); and (F) PRSS3 (P=0.317). The patients were divided into two groups according to the expression of hub genes. The blue curve represents the low-expression group, while the green curve represents the high-expression group. CTAG2, cancer/testis antigen 2.

    Techniques Used: Expressing

    Univariate and multivariate Cox regression analysis of clinicopathological data correlated with overall survival in hepatocellular carcinoma patients.
    Figure Legend Snippet: Univariate and multivariate Cox regression analysis of clinicopathological data correlated with overall survival in hepatocellular carcinoma patients.

    Techniques Used: Expressing

    Association of CTAG2 expression with the clinicopathological features of hepatocellular carcinoma patients from The Cancer Genome Atlas database.
    Figure Legend Snippet: Association of CTAG2 expression with the clinicopathological features of hepatocellular carcinoma patients from The Cancer Genome Atlas database.

    Techniques Used: Expressing

    CTAG2 exhibited increased expression in hepatocellular carcinoma tissues obtained from patients at our hospital, as compared with that in adjacent tissues. Representative micrographs show immunohistochemical staining of CTAG2 in (A) adjacent and (B) tumor tissues (magnification, ×40). The square frame indicate the region that is magnified in the insert (magnification, ×400; scale bar, 500 µm). (C) Immunoreactive scores for CTAG2 staining in tumor tissues were significantly higher as compared with those in adjacent tissues. The P-value was obtained using the Wilcoxon rank-sum test (all paired samples, n=46, P<0.001). CTAG2, cancer/testis antigen 2.
    Figure Legend Snippet: CTAG2 exhibited increased expression in hepatocellular carcinoma tissues obtained from patients at our hospital, as compared with that in adjacent tissues. Representative micrographs show immunohistochemical staining of CTAG2 in (A) adjacent and (B) tumor tissues (magnification, ×40). The square frame indicate the region that is magnified in the insert (magnification, ×400; scale bar, 500 µm). (C) Immunoreactive scores for CTAG2 staining in tumor tissues were significantly higher as compared with those in adjacent tissues. The P-value was obtained using the Wilcoxon rank-sum test (all paired samples, n=46, P<0.001). CTAG2, cancer/testis antigen 2.

    Techniques Used: Expressing, Immunohistochemical staining, Staining

    Association of CTAG2 expression with the clinicopathological features of hepatocellular carcinoma patients from the First Affiliated Hospital of China Medical University.
    Figure Legend Snippet: Association of CTAG2 expression with the clinicopathological features of hepatocellular carcinoma patients from the First Affiliated Hospital of China Medical University.

    Techniques Used: Expressing



    Similar Products

    Image Search Results